Form 4: Zentalis Pharmaceuticals Principal Accounting Officer Sells Shares to Cover Tax Obligations and Under 10b5-1 Plan

Vincent Vultaggio, Principal Accounting Officer of Zentalis Pharmaceuticals, sold 1,603 shares of common stock on October 4, 2024, to cover tax obligations and under a pre-arranged 10b5-1 trading plan.

Summary

• On October 4, 2024, Vincent Vultaggio, the Principal Accounting Officer of Zentalis Pharmaceuticals, sold 1,603 shares of the company's common stock.
• The sale was executed at a price of $3.18 per share.
• A portion of the shares were sold automatically to satisfy withholding tax obligations upon the vesting of restricted stock units.
• The remaining shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Vultaggio on September 20, 2023.
• Following the transaction, Vultaggio directly owns 33,855 shares of Zentalis Pharmaceuticals.

Sentiment

Score: 5

Explanation: The document describes a routine stock sale by an officer, partly to cover tax obligations and partly under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Sales by company insiders are a common occurrence and are often related to personal financial planning or diversification. The use of a 10b5-1 plan suggests the insider planned the transaction in advance.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the small volume of shares sold.

Key Dates